Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22489884 | 0.85 | PRMT6 (0.51) | PRMT6CYP19A1NSD2SMN1; SMN2LMNA | |
| SCHEMBL22489446 | 0.85 | PRMT6 (0.55) | PRMT6CYP19A1NSD2SMN1; SMN2LMNA | |
| SCHEMBL22489905 | 0.84 | PRMT6 (0.48) | PRMT6CYP19A1CNR1NSD2SMN1; SMN2 | |
| SCHEMBL22489911 | 0.83 | CYP19A1 (0.73) | PRMT6CYP19A1LMNAKMT2A | |
| SCHEMBL22489891 | 0.80 | NAMPT (0.54) | PRMT6CYP19A1CNR1SMN1; SMN2LMNA | |
| SCHEMBL44570 | 0.76 | CNR1 (0.40) | CYP19A1CNR1LMNAKAT6AKMT2A | |
| SCHEMBL1848502 | 0.76 | SMN1; SMN2 (0.43) | CYP19A1CNR1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL22489742 | 0.75 | CYP19A1 (0.53) | PRMT6CYP19A1SMN1; SMN2LMNAPRKCI | |
| SCHEMBL22489733 | 0.75 | PRMT6 (0.55) | PRMT6CYP19A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL22489791 | 0.75 | NAMPT (0.54) | PRMT6CYP19A1SMN1; SMN2LMNAROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, SSTR5, FFAR3 | PRMT6 3537/4885CYP19A1 2140/4885CNR1 57/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | PRMT6 3062/4885CYP19A1 1627/4885CNR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.